Marco Sealey PhD
  • Previous Head of Discovery & Research of CALYXHA.

  • Entrepreneur, cell biologist and drug discovery enthusiast. Over 5 years of experience developing and inventing in-vitro cell systems in academia and biotech to prove mechanisms of tissue degeneration.

  • Senior postdoc at the Konrat group, Department for Structural and Computational Biology, Max Perutz Laboratories, Vienna – Austria (2015 - 2019). Topic of research: drug discovery and mode of action (MoA) of small molecules and in-vitro-Cell NMR spectroscopy (ex-cell NMR).

  • Postdoctoral researcher at the Warren group, Max Perutz Laboratories, Vienna – Austria (2008-2014). Topic: the secretory pathway and cytoskeleton of trypanosomes.

  • Visiting scientist, Department of Pathology, Cambridge University - UK (2007). Studies on endocytosis in trypanosomes as a drug target.

  • Primary research interests: molecular cell biology, biochemistry, drug discovery, drug targets and mode of action, molecular parasitology, membrane trafficking and the cytoskeleton.

  • Peer-reviewed publications on drug discovery in trypanosomes, trypanosome endoplasmic reticulum exit sites, cytoskeleton, cell biology and NMR spectroscopy, and inventor on CALYXHA related patent families.

  • Education: Ph.D. in Biochemistry and Molecular Biology, Institute of Parasitology and Biomedicine Lopez Neyra, University of Granada – Spain (2007 ). Topic: Genetic validation of the sterol biosynthetic pathway in trypanosomes as a potential drug target.